BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/14/2017 3:13:08 AM | Browse: 1044 | Download: 1296
 |
Received |
|
2017-07-28 02:21 |
|
Peer-Review Started |
|
2017-07-28 02:46 |
|
To Make the First Decision |
|
2017-08-10 00:28 |
|
Return for Revision |
|
2017-08-14 13:24 |
|
Revised |
|
2017-08-16 21:53 |
|
Second Decision |
|
2017-08-30 00:48 |
|
Accepted by Journal Editor-in-Chief |
|
2017-08-30 22:30 |
|
Accepted by Executive Editor-in-Chief |
|
2017-09-05 18:25 |
|
Articles in Press |
|
2017-09-05 18:25 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-09-07 05:45 |
|
Publish the Manuscript Online |
|
2017-09-14 03:13 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Konstantinos Papamichail and Adam S Cheifetz |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Konstantinos Papamichail, FEBG, MD, PhD, Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, Brookline, MA 02215, United States. kpapamic@bidmc.harvard.edu |
| Key Words |
Inflammatory bowel disease; Infliximab; Adalimumab; magnetic resonance imaging; Drug monitoring; Fistula healing |
| Core Tip |
Defining and predicting deep remission is important to guide the management of patients with perianal fistulizing Crohn’s disease (CD). Deep remission, defined as complete fistula healing based on objective endoscopic and radiologic findings, should be the goal of care in the treatment of patients with perianal CD. Currently, anti-tumor necrosis factor (anti-TNF) are the standard of care for perianal CD, but long-term outcomes are disappointing. Data suggests that higher infliximab concentrations are associated with better clinical outcomes in patients with perianal fistulising CD and thus therapeutic drug monitoring may be a valid therapeutic strategy for optimizing anti-TNF therapy towards improved objective outcomes and deep remission. |
| Publish Date |
2017-09-14 03:13 |
| Citation |
Papamichael K, Cheifetz AS. Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy. World J Gastroenterol 2017; 23(34): 6197-6200 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i34/6197.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i34.6197 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
